New launches to drive earnings growth in FY18 & FY19: Glenmark

New launches to drive earnings growth in FY18 & FY19: Glenmark The company has a strong pipeline of products which the company, CMD Glenn Saldanha said adding that new launches will drive earnings for the company in FY18 and FY19. The company has no plans to raise further capital, he said. Glenmark Pharmaceuticals is betting on new drug launches to drive earnings growth for the drug major. The company expects Zetia generic, which it launched in the US earlier in the month, to contribute revenue worth USD 200-250 million in the next 6 months, Chairman and Managing Director Glenn Saldanha Read More


Glenmark to invest $300m in 3 years to grow 20%

Glenmark to invest $300m in 3 years to grow 20% Mumbai: Glenmark Pharma will invest $300 million for the next three years to grow its revenue at a CAGR of 15-20%, led by sales of specialty drugs and complex generics in oncology, dermatology and respiratory in its top markets — US, India and Europe. The company will invest 11% of its sales on research and development, up from existing 9%, while the proposed capital expansion of $100 million each year will be funded by internal accruals, Glenn Saldanha, chairman and managing director of the $1.2-billion Glenmark Pharmaceuticals, said here. The Read More


We plan to out-license our entire novel drugs pipeline: Glenmark CMD

We plan to out-license our entire novel drugs pipeline: Glenmark CMD Glenmark CMD Glenn Saldanha shares his vision of how he plans to grow the business in a challenging environment Mumbai: Indian pharmaceutical companies are on the cusp of a transformation from being generic drug makers to creating a pipeline of complex generics, speciality and innovative products through enhanced focus on research and development (R&D). Glenmark Pharmaceuticals Ltd’s growth strategy also revolves around making this transition. In fact, it is among the few Indian firms that started investing in new drug development way back in the year 2000. But unlike Read More


Glenmark Unveils its Strategic Blueprint for Transition Into an Innovation-led Global Pharmaceutical Organization in the Next Decade

Glenmark Unveils its Strategic Blueprint for Transition Into an Innovation-led Global Pharmaceutical Organization in the Next Decade – Leverages Company’s Industry-leading Capabilities to Expand Discovery and Development of Glenmark’s Robust Generics and Innovative Portfolio – Focuses Resources on Growth Catalysts – Focus on innovative new molecular entities (NME) – Filing as many as nine new drug application (NDA)/biologic license application (BLAs) in the next 10 years – Targeting 30 percent of total revenues from specialty and innovation segments over the next decade Glenmark Pharmaceuticals Ltd. (GPL), a global research-driven, integrated pharmaceutical company headquartered at Mumbai, today announced its ‘Strategic Blueprint Read More


Generic Pharma Companies Stand To Gain If Obamacare Repealed: Glenmark

Generic Pharma Companies Stand To Gain If Obamacare Repealed: Glenmark Glenmark Pharmaceuticals Ltd. says generic pharmaceutical companies would get a greater share of the American drug market, if the incoming Republican administration led by U.S. President-Elect Donald Trump were to repeal the Affordable Care Act – popularly known as Obamacare. Glemark unveiled a ten-year strategy plan on Monday, and said oncology, respiratory and dermatology will be key growth areas, going forward. The Mumbai-based pharma company plans to target at least 30 percent of its revenue from the speciality and innovation segment over the next decade. Spends on research and development Read More


ˆ Back To Top